Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Research
Research
Merck KGaA spinout iOnctura touts PI3K inhibitor in eye cancer
In head-to-head comparison of patient tumors, iOnctura’s roginolisib outperformed Gilead’s idelalisib in reducing cancer signaling pathway effectors.
Marissa Russo
Oct 14, 2026 1:42pm
Vir CEO sees chance ‘to do more deals’ after $1.9B Gilead pact
Oct 14, 2026 8:30am
How Nobel-winning optogenetics is being harnessed by biotechs
Oct 9, 2026 9:30am
‘It’s just survival’: Why a third of Boston lab space sits empty
Oct 8, 2026 8:00am
Mimetic’s peptide shows promise in reducing neuropathic pain
Oct 6, 2026 11:00am
How NIH’s Kleinstreuer reduces animal tests without ‘backlash’
Oct 6, 2026 8:00am
